First oncolytic virus edges towards approval in surprise vote - PubMed (original) (raw)

First oncolytic virus edges towards approval in surprise vote

Cormac Sheridan. Nat Biotechnol. 2015 Jun.

No abstract available

PubMed Disclaimer

Similar articles

• Cancer-fighting viruses win approval.
  Ledford H. Ledford H. Nature. 2015 Oct 29;526(7575):622-3. doi: 10.1038/526622a. Nature. 2015. PMID: 26511559 No abstract available.
• Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
  Kohlhapp FJ, Zloza A, Kaufman HL. Kohlhapp FJ, et al. Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044. Drugs Today (Barc). 2015. PMID: 26488034 Review.
• The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
  Andtbacka RH. Andtbacka RH. Clin Adv Hematol Oncol. 2016 Aug;14(8):576-9. Clin Adv Hematol Oncol. 2016. PMID: 27487099 No abstract available.
• Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
  Kohlhapp FJ, Kaufman HL. Kohlhapp FJ, et al. Clin Cancer Res. 2016 Mar 1;22(5):1048-54. doi: 10.1158/1078-0432.CCR-15-2667. Epub 2015 Dec 30. Clin Cancer Res. 2016. PMID: 26719429 Review.
• The use of oncolytic virotherapy in the neoadjuvant setting.
  Thomas RJ, Bartee E. Thomas RJ, et al. J Immunother Cancer. 2022 Apr;10(4):e004462. doi: 10.1136/jitc-2021-004462. J Immunother Cancer. 2022. PMID: 35414592 Free PMC article. Review.

Cited by

• Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles.
  Lin J, Wang X, Ni D, Chen Y, Chen C, Liu Y. Lin J, et al. ACS Mater Au. 2023 Jul 27;3(6):584-599. doi: 10.1021/acsmaterialsau.3c00035. eCollection 2023 Nov 8. ACS Mater Au. 2023. PMID: 38089659 Free PMC article. Review.
• The changing landscape of clinical trial and approval processes in China.
  Zhou Q, Chen XY, Yang ZM, Wu YL. Zhou Q, et al. Nat Rev Clin Oncol. 2017 Sep;14(9):577-583. doi: 10.1038/nrclinonc.2017.10. Epub 2017 Feb 14. Nat Rev Clin Oncol. 2017. PMID: 28195238 Review.
• Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
  Jin J, Wang R, Yang J, Hu H, Wang D, Cai L, Fang Z, Dong S, Hu S, Wang Y, Liu B. Jin J, et al. Hum Gene Ther. 2022 Jun;33(11-12):649-663. doi: 10.1089/hum.2021.277. Hum Gene Ther. 2022. PMID: 35272497 Free PMC article.
• Viral oncolytic immunotherapy in the war on cancer: Infection control considerations.
  Robilotti EV, Kumar A, Glickman MS, Kamboj M. Robilotti EV, et al. Infect Control Hosp Epidemiol. 2019 Mar;40(3):350-354. doi: 10.1017/ice.2018.358. Epub 2019 Feb 15. Infect Control Hosp Epidemiol. 2019. PMID: 30767816 Free PMC article. Review.
• Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.
  Tian L, Liu T, Jiang S, Cao Y, Kang K, Su H, Ren G, Wang Z, Xiao W, Li D. Tian L, et al. Gene Ther. 2023 Feb;30(1-2):64-74. doi: 10.1038/s41434-021-00256-8. Epub 2021 Oct 4. Gene Ther. 2023. PMID: 34602608

References

1. 1. Sci Transl Med. 2014 Mar 5;6(226):226ra32 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information